Vabysmo
Regeneron’s High-Dose Eylea Launch Takes Off, Rivals Roche’s Vabysmo
Anika Sharma
Roche’s increased sales for its extended-release treatment for macular degeneration, Vabysmo, indicate that consumers are willing to try new therapies. ...
Roche’s Vabysmo Preserves RVO Patients’ Vision with 4-Month Treatment Intervals in Phase III Trials
Anika Sharma
Roche has unveiled promising long-term findings from the global phase III BALATON and COMINO trials, which investigated the extended treatment ...
Regeneron’s High-Dose Eylea Demonstrates Persistence as FDA Decision Looms
SG Tylor
While awaiting an FDA decision regarding a higher-dose version of Eylea (aflibercept), Regeneron has consistently emphasized the durability of their ...
Vabysmo, Roche’s Top Eye Medicine, Crosses Blockbuster Threshold Ahead of Competitors
SG Tylor
According to Roche’s pharma chief, Teresa Graham, their eye drug Vabysmo is currently experiencing significant momentum. Since its FDA approval ...
Roche’s Vabysmo Shows Promising Vision Loss Improvement at ASRS
SG Tylor
Source – Roche On July 20, Roche announced that they will be presenting data from their ophthalmology portfolio in 25 ...
